SCHEMBL23027798

SCHEMBL23027798

O=C1c2ccccc2C(=O)N1CCc1csc(-c2nc(CCN3C(=O)c4ccccc4C3=O)cs2)n1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.78
SMN1; SMN2 Q16637 3/20 0.78
ALDH1A1 P00352 5/20 0.76
L3MBTL1 Q9Y468 2/20 0.76
HPGD P15428 2/20 0.76
PKM P14618 1/20 0.74
MAPT P10636 5/20 0.72
POLB P06746 3/20 0.72
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
RXFP1 Q9HBX9 1/20 0.70
CYP1A2 P05177 2/20 0.64
CYP2C9 P11712 2/20 0.64
CYP2C19 P33261 2/20 0.64
CYP2D6 P10635 1/20 0.64
HSD17B10 Q99714 1/20 0.56
KDM4E B2RXH2 2/20 0.52
GLS O94925 1/20 0.49
PDE10A Q9Y233 1/20 0.48
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23027822 0.91 LMNA (0.83) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL23027807 0.88 LMNA (1.00) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL23027811 0.87 LMNA (1.00) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL23027794 0.87 LMNA (0.65) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL17261495 0.86 PKM (0.72) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL4604023 0.85 PKM (0.70) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL29451720 0.85 PKM (0.70) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL4410471 0.85 LMNA (0.62) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL23027787 0.84 POLB (0.84) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD
Hydrochloric Acid SCHEMBL9381859 0.84 PKM (0.68) LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202783-A1 Use Of ADAM9 Inhibitor As Immunomodulator CHINA MEDICAL UNIVERSITY (TW) 2022-06-30 US disclosed
US-11357759-B2 Composition including ADAM9 inhibitor and the use thereof CHINA MEDICAL UNIVERSITY (TW) 2022-06-14 US disclosed
US-20210052562-A1 Composition Including ADAM9 Inhibitor And The Use Thereof CHINA MEDICAL UNIVERSITY (TW) 2021-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11357759-B2 Composition including ADAM9 inhibitor and the use thereof ADAM9, ADAM8, ADAM17 LMNA 1059/4885SMN1; SMN2 2906/4885ALDH1A1 818/4885
US-20220202783-A1 Use Of ADAM9 Inhibitor As Immunomodulator ADAM9, ADAM17, ADAM10 LMNA 4779/4885SMN1; SMN2 3902/4885ALDH1A1 736/4885
US-20210052562-A1 Composition Including ADAM9 Inhibitor And The Use Thereof ADAM9, ADAM8, ADAM17 LMNA 1059/4885SMN1; SMN2 2906/4885ALDH1A1 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.